Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
Presenter: Edward Kerwin, M.D.SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.
加利福尼亞州聖地亞哥和中國太倉，2024年5月7日（GLOBE NEWSWIRE）——Connect Biopharma Holdings Limited（納斯達克股票代碼：CNTB）（“Connect Biopharma” 或 “公司”）是一家全球臨床階段的生物製藥公司，致力於通過開發源自T細胞研究的療法來改善慢性炎症性疾病患者的生活，今天公佈了其全球2b期試驗的數據針對中度至重度哮喘患者的rademikibart被接受爲即將到來的ATS 2024海報展示的最新摘要國際會議將於2024年5月17日至22日在加利福尼亞州聖地亞哥舉行。
Poster Presentation Details:
海報 演示詳情：
Title: Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)
標題：使用Rademikibart觀察到中度至重度不受控制的哮喘（CBP-201-WW002）患者的肺功能和哮喘控制得到改善
Presenter: Edward Kerwin, M.D.
主持人：愛德華·克文，醫學博士
Session: Poster Discussion D21: Terminator: Control of Airway Inflammation and Immune Response in Asthma
會議：海報討論 D21：終結者：控制哮喘的氣道炎症和免疫反應
Session Date and Time: Wednesday, May 22, 2024 at 8:15 AM – 10:15 AM PT
會議日期和時間：太平洋時間 2024 年 5 月 22 日星期三上午 8:15 — 上午 10:15
Location: San Diego Convention Center, Room 31A-C (Upper Level)
地點：聖地亞哥會議中心，31A-C室（上層）
Additionally, the poster presentation will be available as an ePoster on the ATS 2024 International Conference website, and will be available for viewing May 19 - 22, 2024.
此外，海報演示將作爲電子海報在ATS 2024國際會議網站上發佈，並將於2024年5月19日至22日可供觀看。
About Connect Biopharma Holdings Limited
關於 Connect 生物製藥控股有限公司
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company's second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/
Connect Biopharma是一家全球性的臨床階段生物製藥公司，運用其在T細胞生物學方面的專業知識和對藥物發現行業的深入了解，開發治療慢性炎症性疾病的創新療法，目標是改善全球數百萬受影響者的生活。該公司正在建立豐富的專有小分子和抗體產品線，使用功能性T細胞檢測，對照經過驗證的免疫靶標篩選和發現有效的候選產品。該公司的主要候選產品rademikibart（前身爲 CBP-201）是一種抗體，旨在靶向正在開發的用於治療特應性皮炎（AD）和哮喘的白介素-4受體α受體（IL-4Rα）。該公司的第二種候選產品icanbelimod（前身爲 CBP-307）是S1P1 T細胞受體的調節劑，正在開發用於治療潰瘍性結腸炎（UC）。欲了解更多信息，請訪問： https://www.connectbiopharm.com/
INVESTOR CONTACT:
投資者聯繫人：
Tim McCarthy
蒂姆·麥卡錫
LifeSci Advisors
生命科學顧問
